Research Fields
Biomarker Discovery
Liquid Biopsy (LBx)
Evaluation of liquid biopsy as a clinical diagnostic tool
Our goal is to develop various liquid biopsy biomarkers, such as CTCs and ctDNA, from cancer patients to provide valuable information for patient care and contribute to precision medicine.
Bioinformatics (BI)
Identification of novel biomarkers using clinical information and diverse databases
Our goal is to contribute to precision medicine by developing a prognostic prediction model or discovering new therapeutic targets using clinical information and various data.
Ant-cancer Therapy
Antibody Screening
Research on developing innovative antibody drugs
To address unmet clinical needs, we are deeply analyzing the pathological mechanisms of target proteins and discovering therapeutic antibodies with potential for treatment. To this end, we systematically analyze the mechanism of action (MOA) and clinical trial data of various drugs to establish the optimal development strategy and design target-centered personalized research.
Immuno-oncology
Development and research of immune checkpoint inhibitors
Our research focuses on developing a novel immune checkpoint inhibitor that specifically targets a particular immune cell subtype to stimulate immune response. Recognizing the diverse roles of various immune checkpoint targets in the tumor microenvironment, we are pursuing multiple drug development strategies tailored to target specific immune cell subtypes for each target.
Immunocytokine
Development of antibody-cytokine fusion proteins
We aim to enhance anti-tumor efficacy by converting cold tumors into hot tumors through the development of immunocytokines, which combine cytokines with antibodies targeting specific antigens. These immunocytokines are designed to directly kill cancer cells and indirectly activate immune cells in the tumor microenvironment (TME).
CAR-X Immunotherapy
Development of allogeneic CAR-X and NK cell immunotherapies
To overcome CAR T cell therapy, we are investigating allogeneic cell therapies using an off-the-shelf approach, where a universal product is created from a single donor and can be administered to multiple patients. In particular, We focus on developing therapies based on iPSC-derived and cord blood-derived NK and T cells, employing innovative gene delivery technologies and efficient large-scale manufacturing strategies.
Abscopal
Study on enhancing the abscopal effect and elucidating its mechanism using phototherapy
We aims to investigate the systemic therapeutic efficacy, including the abscopal effect, of photothermal or photodynamic therapy using tumor-targeted photosensitizers. We will explore the underlying immune mechanisms of the abscopal effect and investigate the synergistic effects of combining immunostimulatory cytokines and immune checkpoint inhibitors to enhance the abscopal effect in treatment-resistant tumors.
Antibody - Omomyc, siRNA conjugate
Development of antibody-Omomyc, asymmetric siRNA therapeutics
Our goal is to improve the delivery of Omomyc and asymmetric siRNA to tumors by conjugating them with antibodies. This approach is expected to increase the specificity of drug delivery, reducing off-target effects, and inducing apoptosis of cancer cells by targeting MYC protein and other cancer-related genes within the tumor microenvironment.
Biodefense
Bio Vaccine
Investigation of preventive and curative strategies for Disease X
We have established a platform technology that leverages various biotech techniques, from recombinant proteins to genetic materials, to rapidly respond to a wide range of infectious diseases. Using this platform, we are swiftly developing vaccines and therapeutics against pathogens and novel viruses that could be exploited for biological threats.